Shares of Boston Scientific Corporation (NYSE: BSX) surged more than 3 percent Monday's following news that the company's Watchman device was approved by the U.S. FDA.
According to RBC Capital Markets analysts Glenn Novarro, Watchman is a "novel left atrial appendage closure device for the treatment of atrial fibrillation" that has already been implanted in more than 10,000 patients in 75 countries.
The approval came slightly ahead of schedule, according to Deutsche Bank analyst Kristen Stewart, who viewed it as a positive and maintained a Hold rating on the stock.
The device was expected to generate $500 million in sales over the next five years, according to Wedbush analyst Tao Levy.
Credit Suisse also viewed the news as a positive. Analyst Bruce Nudell revised 2015/2020 EPS estimates of $0.90/$1.44 from $0.90/$1.41 and increased the DCF-based price target from $18 to $19. Nudell maintained an Outperform rating.
Boston Scientific recently traded at $17.16, up 3.3 percent.
Latest Ratings for BSX
| Mar 2015 | BMO Capital | Maintains | Outperform | |
| Mar 2015 | Oppenheimer | Maintains | Perform | |
| Feb 2015 | Deutsche Bank | Maintains | Hold |
View More Analyst Ratings for BSX
View the Latest Analyst Ratings
See more from Benzinga
-
3 Companies That Could Be Negatively Impacted By Johnson & Johnson Sale Of Cordis
-
Boston Scientific Soars 11% After Settling Dispute With Johnson & Johnson
© 2015 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.